Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/28164
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY Antimicrobial Surveillance Program (1998-1999) |
Author: | Bell, J. Turnidge, J. Pfaller, M. Jones, R. |
Citation: | Diagnostic Microbiology and Infectious Disease, 2002; 43(4):315-318 |
Publisher: | Elsevier Science Inc |
Issue Date: | 2002 |
ISSN: | 0732-8893 1879-0070 |
Abstract: | Fluoroquinolones, especially the newer agents, have an increased role in the management of respiratory tract infections worldwide. In the SENTRY Antimicrobial Surveillance Program for the Asia-Pacific Region for 1998 and 1999, 630 Streptococcus pneumoniae, 583 Hemophilus influenzae and 274 Moraxella catarrhalis isolates were examined to determine the comparative activity of the new fluoroquinolone, gatifloxacin, compared with those of ciprofloxacin, levofloxacin and trovafloxacin. Gatifloxacin was highly active against all three species. Decreased susceptibility (MIC >/=2 microg/mL) to gatifloxacin was noted in only seven strains of S. pneumoniae (3 of which were resistant); in three strains of H. influenzae (MIC >/= 0.12 microg/mL), and 2 M. catarrhalis (MIC > 2 microg/mL). |
Keywords: | Humans Haemophilus influenzae Streptococcus pneumoniae Respiratory Tract Infections Fluoroquinolones Anti-Infective Agents Microbial Sensitivity Tests Population Surveillance Drug Resistance, Bacterial Asia Gatifloxacin Moraxella catarrhalis |
DOI: | 10.1016/S0732-8893(02)00404-2 |
Published version: | http://dx.doi.org/10.1016/s0732-8893(02)00404-2 |
Appears in Collections: | Aurora harvest 6 Molecular and Biomedical Science publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.